- Inclusion Body Myositis: Background, Pathophysiology, Epidemiology
- Ongoing Developments in Sporadic Inclusion Body Myositis
- B. Essentials of Assessment
- Muscle Aging, Inclusion-Body Myositis and Myopathies - eBook
Presse Med. Primary Sjogren's syndrome associated with inclusion body myositis.
Inclusion Body Myositis: Background, Pathophysiology, Epidemiology
Rheumatology Oxford. Inclusion body myositis associated with celiac sprue and idiopathic thrombocytopenic purpura. South Med J. Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases. Association of inclusion body myositis with subacute cutaneous lupus erythematosus.
Rheumatol Int. Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol. Inclusion body myositis evolving in systemic lupus erythematosus?
Ongoing Developments in Sporadic Inclusion Body Myositis
A case report. Creutzfeldt-Jakob disease and inclusion body myositis: abundant disease-associated prion protein in muscle. Clinical and serological characteristics of Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis.
Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Inclusion body myositis--sensory dysfunction revealed with quantitative determination of somatosensory thresholds. Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis.
A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.
BMJ Open. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Inclusion body myositis and myopathies.
- Rare Disease Database.
- Sporadic Inclusion Body Myositis - NORD (National Organization for Rare Disorders).
- Cleveland Clinic Menu!
Sarcoplasmic redistribution of nuclear TDP in inclusion body myositis. Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep. Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol.
B. Essentials of Assessment
Long-term observational study of sporadic inclusion body myositis. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. A pilot randomized trial of oxandrolone in inclusion body myositis. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
Inclusion body myositis: treatment with intravenous immunoglobulin. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Treatment of inclusion-body myositis with IVIg: A double blind, placebo-controlled study.
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Muscle Study Group. Randomized pilot trial of betaINF1a Avonex in patients with inclusion body myositis. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Pilot trial of etanercept in the treatment of inclusion-body myositis. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.
In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem. Hicks J. Comprehensive rehabilitative management of patients with polymyositis and dermatomyositis. In: Dalakas M, ed. Polymyositis and Dermatomyositis. Boston, Mass: Butterworth-Heinemann; Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.
Can J Gastroenterol. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. A prospective natural history study of inclusion body myositis: implications for clinical trials. Disease progression in sporadic inclusion body myositis: observations in 78 patients.
Inclusion body myositis: clinical and pathological boundaries. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol. Transthyretin ValIle, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle.
- In The Thick Of It.
- Sporadic inclusion body myositis: the genetic contributions to the pathogenesis?
- Inclusion Body Myositis: Background, Pathophysiology, Epidemiology.
Barkhaus PE. The electrodiagnostic evaluation of the patient with suspected myopathy. In Kincaid JC, ed. Quantitative electrophysiologic studies in sporadic inclusion body myositis. Barohn RJ. The therapeutic dilemma of inclusion body myositis. Human muscle cells express a functional costimulatory molecule distinct from B7.
The role of quantitative electromyography in inclusion body myositis. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis.
Neuropathol Appl Neurobiol. Inclusion body myositis mimicking motor neuron disease.
Muscle Aging, Inclusion-Body Myositis and Myopathies - eBook
Inclusion body myositis: morphological clues to correct diagnosis. Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. Can J Neurol Sci. Beta-chemokine receptor expression in idiopathic inflammatory myopathies. Alpha-chemokine receptors CXCR and their ligands in idiopathic inflammatory myopathies. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis.
Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Peripheral neuropathy associated with hereditary and sporadic inclusion body myositis: confirmation by electron microscopy and morphometry.
Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Preservation of in vitro muscle fiber function in dermatomyositis and inclusion body myositis: a single fiber study. Li M, Dalakas MC. The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis. Inclusion body myositis: no evidence for a neurogenic component.
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. Inclusion body myositis: expression of extracellular signal-regulated kinase and its substrate.